Genmab A/S
GMAB
$20.25
$0.050.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 920.51M | 816.36M | 779.45M | 603.24M | 687.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 920.51M | 816.36M | 779.45M | 603.24M | 687.03M |
| Cost of Revenue | 48.16M | 40.23M | 27.42M | 26.94M | 18.19M |
| Gross Profit | 872.35M | 776.13M | 752.04M | 576.31M | 668.84M |
| SG&A Expenses | 178.50M | 127.46M | 129.00M | 124.78M | 134.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 596.52M | 504.11M | 517.42M | 486.61M | 434.25M |
| Operating Income | 323.99M | 312.25M | 262.03M | 116.63M | 252.78M |
| Income Before Tax | 514.78M | 253.31M | 306.90M | 249.86M | 145.37M |
| Income Tax Expenses | -34.73M | 66.75M | 103.74M | 56.93M | 43.89M |
| Earnings from Continuing Operations | 549.50M | 186.55M | 203.16M | 192.93M | 101.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 549.50M | 186.55M | 203.16M | 192.93M | 101.49M |
| EBIT | 323.99M | 312.25M | 262.03M | 116.63M | 252.78M |
| EBITDA | 336.56M | 324.78M | 271.99M | 125.37M | 258.12M |
| EPS Basic | 8.65 | 2.94 | 3.15 | 2.95 | 1.55 |
| Normalized Basic EPS | 5.23 | 2.31 | 3.12 | 2.34 | 1.21 |
| EPS Diluted | 8.57 | 2.92 | 3.13 | 2.94 | 1.54 |
| Normalized Diluted EPS | 5.18 | 2.30 | 3.10 | 2.33 | 1.20 |
| Average Basic Shares Outstanding | 63.53M | 63.49M | 64.44M | 65.30M | 65.34M |
| Average Diluted Shares Outstanding | 64.15M | 63.91M | 64.88M | 65.66M | 66.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
